The report about 'Global Breast Cancer Liquid Biopsy Market' By Indicators or Circulating Biomarkers(Circulating Tumour Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles, Others).Based on End-users(Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories). By Region (North America, Europe, Asia-Pacific, Middle-East and Africa, South America). With a market size of USD 104.42 Mn in 2020, the Global Breast Cancer Liquid Biopsy Market Size will grow to USD 604.71 Mn by 2030 with a CAGR of 19.2%.
To know more about the report, Click on the link :- https://www.strategicmarketresearch.com/market-report/breast-cancer-liquid-biopsy-market-
Key Factors that are expediting the Market growth
Key factors that promote the growth of the breast cancer liquid biopsy market are the rise in prevalence of breast cancer, technological advancements in breast cancer, use of liquid biopsy instruments, increase in preference for non-invasive procedures, advantages of over solid tumour biopsy, and increase in patient awareness towards minimally invasive breast cancer liquid biopsy procedures.
Based on Indicators, The Circulating Cell-free DNA (cfDNA) Segment is predicted to hold a Major Market Share.
The Circulating Cell-free DNA (cfDNA) Segment continued to lead the market due to its ability to detect emerging genomic alterations associated with drug resistance, the potential to clarify cancer prognosis and diagnose cancer recurrence or progression and the ability to detect emerging genomic alterations associated with drug resistance are attributed to this Breast Cancer liquid biopsy screening market.
Based on end-user, The Reference Laboratories Segment is the most significant global breast cancer liquid biopsy market.
Reference laboratories are extensive, well-equipped laboratories with genetic testing facilities that receive many samples from hospitals and private practitioners.
NORTH AMERICA SIGNIFICANTLY DOMINATED THE LIQUID BIOPSY MARKET IN 2020
Among the regions, North America dominated the global liquid biopsy market in 2020. This dominance is attributed to the increased healthcare expenditure, easy accessibility to technologically advanced instruments, increased awareness of different types of cancer, and advanced diagnostic technologies. Furthermore, the rising cancer occurrence in the United States has exponentially boosted the liquid biopsy industry.
The American Cancer Society (2020) estimates that there will be 1.8 million new cancer diagnoses and more than 6 lakh deaths in the United States. As a result, the liquid biopsy market in North America has been driven by an increase in cancer diagnoses among the US population. Other factors include easy access to technologically advanced instruments, developed healthcare systems in the United States and Canada, and many leading national clinical laboratories.
Soon, The Asia Pacific is most likely to be the most profitable market. The market is growing due to rising government investments in establishing advanced hospitals and the growing penetration of multiple diagnostic laboratories in the region. Moreover, the increasing incidences of cancer and the presence of a colossal population are boosting the need to develop technologically advanced healthcare units, spurring the demand for liquid biopsy in the Asia Pacific market.
IMPORTANT MARKET PLAYERS:
Some of the pivotal players in the Global Breast Cancer Liquid Biopsy Market field
include Johnson & Johnson (Janssen Diagnostics), F. Hoffmann-La Roche Ltd, Qiagen, Janssen, Diagnostics, Guardant Health Inc., Myriad Genetics, Adaptive Biotechnologies, Epic Sciences, Fluxion Biosciences Inc., Biodesix, Illumina Inc., Bio-Rad Laboratories, Biocept Inc,)
Recent Developments